39 results
6-K
EX-99.3
SPRC
SciSparc Ltd
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
, causing problems in social interaction and communication. The term “spectrum” in autism spectrum disorder refers to the wide range of symptoms
F-1
EX-10.7
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
, transfer, value added tax, real and personal property, withholding, payroll, employment, escheat, social security, disability, national security, health … of appropriate social security, health tax contributions or other compulsory payments; and
9.7.3. The Grantee agrees to the trust agreement signed between
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
restrictive, charging fees or altering its algorithms that determine the placement, display and accessibility of search results and social media updates … or customer support, especially on blogs, social media websites or our sites, could rapidly and severely diminish consumer views of our products
6-K
EX-99.1
SPRC
SciSparc Ltd
29 Jan 24
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
4:00pm
and socializes with others, causing problems in social interaction and communication. The term “spectrum” in autism spectrum disorder refers to the wide range
6-K
EX-4.1
170 jop0b2v
28 Nov 23
Report of Foreign Private Issuer
4:01pm
6-K
EX-99.1
x3skp
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-4.1
19ci600zah8r4le0nupa
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
EX-99.2
lr38tk 7s
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
rxl68upv5442 s8
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
EX-99.1
ms2b alefbe
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
EX-99.1
1ec bqyk8
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
6-K
EX-10.3
xjalss2qk5mj
4 Apr 23
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
7:07am
6-K
EX-99.1
92e31ysxv53sbu
8 Nov 22
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
7:33am
6-K
EX-99.3
euayut9usvdylnl 8z
30 Sep 22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
7:27am
6-K
EX-99.1
xyuw20
11 Aug 22
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:42am
6-K
EX-99.1
rufntj
24 Jun 22
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:52am
6-K
EX-99.1
uhfei6kw emij9nu0
22 Feb 22
Report of Foreign Private Issuer
9:05am